Clinical Trial Update: A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1 [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 study evaluating safety and tolerability of multiple doses of ISIS-DMPKRx in adults with myotonic dystrophy type 1.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myotonic Dystrophy Type

Drugs mentioned

• ISIS-DMPKRx ( ISIS-DMPKRx)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Myotonic Dystrophy Type 1 | Phase 1, Phase 2 | Status: COMPLETED